Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12678475 | 0.91 | SMN1; SMN2 (0.41) | SMN1; SMN2ALOX5CD274PDCD1GRM2 | |
| SCHEMBL12678468 | 0.89 | ALOX5 (0.38) | ALOX5TSHRNPSR1MALT1GRM2 | |
| SCHEMBL8064334 | 0.89 | TSHR (0.39) | SMN1; SMN2ALOX5TSHRNPSR1CD274 | |
| SCHEMBL8815542 | 0.80 | SLC6A7 (0.36) | ALOX5GRM2GRIN1GRIN2B | |
| SCHEMBL12678479 | 0.80 | GRIN1 (0.36) | ALOX5GRM2GRIN1GRIN2B | |
| SCHEMBL12678446 | 0.79 | DRD2 (0.42) | SMN1; SMN2GRIN1GRIN2BPOLBDRD4 | |
| SCHEMBL12678473 | 0.77 | BACE1 (0.35) | SMN1; SMN2ALOX5GRM2GRIN1GRIN2B | |
| SCHEMBL8066822 | 0.76 | PGR (0.35) | ALOX5GRM2GRIN1GRIN2B | |
| SCHEMBL12678472 | 0.75 | ROCK2 (0.35) | SMN1; SMN2ALOX5GRM2GRIN1GRIN2B | |
| SCHEMBL8813509 | 0.75 | PGR (0.37) | SMN1; SMN2ALOX5GRM2GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | SMN1; SMN2 343/4885ALOX5 580/4885TSHR 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.